Medical Disposables Market Targets US$ 326.4 Billion by 2033

Medical Disposables market
Medical Disposables market

The medical disposables market share is predicted to increase at a compound annual growth rate (CAGR) of 7.1% from 2023 to 2033, with revenues estimated at US$ 153.5 billion in 2022, according to a recently released Future Market Insights analysis. By the end of 2033, the market is projected to reach US$ 326.4 billion. The industry with the largest revenue share in 2022 was Bandages & Wound Dressings, which is expected to increase at a compound annual growth rate (CAGR) of 6.8% from 2023 to 2033.

The rising incidence of Hospital Acquired Infections, an increasing number of surgical procedures, and the growing prevalence of chronic diseases leading to longer hospital admission have been the key factors driving the market.

The subsequent spike in the number of chronic illness cases and a rise in the rate of hospitalizations has fuelled the field of emergency medical disposables growth. The expansion of the medical disposables market is being fuelled by an increase in the prevalence of hospital-acquired illnesses and disorders, as well as a greater focus on infection prevention. For example, the prevalence of healthcare-associated infection in high-income countries ranges from 3.5% to 12%, whereas it ranges from 5.7% to 19.1% in low and medium-income countries.

A growing geriatric population, an increase in the incidence of incontinence issues, mandatory guidelines that must be followed for patient safety at healthcare institutions, and an increase in demand for sophisticated healthcare facilities is driving the medical disposables market.

Get a Sample Copy of the Report :
https://www.futuremarketinsights.com/reports/sample/rep-gb-2227

The market in North America is expected to reach a valuation of US$ 131 Billion by 2033 from US$ 61.7 Billion in 2022. In August 2000, the Food and Drug Administration (FDA) issued guidance concerning healthcare single-use items reprocessed by third parties or hospitals. In this guidance, FDA stated that hospitals or third-party reprocesses would be considered manufacturers and regulated in the exact same manner. A newly used single-use device still has to fulfill the criteria for device activation required by its flagship when it was originally manufactured. Such regulations have been creating a positive impact on the medical disposables market in the U.S. market in specific and the North American market in general.

Competitive Landscape

The key companies in the market are engaged in mergers, acquisitions and partnerships.

The key players in the market include 3M, Johnson & Johnson Services, Inc., Abbott, Becton, Dickinson & Company, Medtronic, B. Braun Melsungen AG, Bayer AG, Smith and Nephew, Medline Industries, Inc., and Cardinal Health.

Some of the recent developments of key Medical Disposables providers are as follows:

  • In April 2019, Smith & Nephew PLC purchased Osiris Therapeutics, Inc. with the goal of expanding its advanced wound management product range.
  • In May 2019, 3M announced the acquisition of Acelity Inc., with the goal of strengthening wound treatment products.

Elevate Strategy: Tap into Analyst Expertise Now:
https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-2227

Market Segments Covered in Medical Disposables Industry Analysis

By Product Type:

  • Surgical Instruments & Supplies
    • Would Closures
    • Procedural Kits & Trays
    • Surgical Catheters
    • Surgical Instruments
    • Plastic Surgical Drapes
  • Infusion and Hypodermic Devices
    • Infusion Devices
    • Hupodermic Devices
  • Diagnostic & Laboratory Disposables
    • Home Testing Supplies
    • Blood Collection Sets
    • Disposable Labware
    • Others
  • Bandages and Wound Dressings
    • Gowns
    • Drapes
    • Face Masks
    • Others
  • Sterilization Supplies
    • Sterile Containers
    • Sterilization Wraps
    • Sterilization Indicators
  • Respiratory Devices
    • Prefilled Inhalers
    • Oxygen Delivery Systems
    • Anesthesia Disposables
    • Others
  • Dialysis Disposables
    • Hemodialysis Products
    • Peritoneal Dialysis Products
  • Medical & Laboratory Gloves
    • Examination Gloves
    • Surgical Gloves
    • Laboratory Gloves
    • Others

By Raw Material:

  • Plastic Resin
  • Nonwoven Material
  • Rubber
  • Metals
  • Glass
  • Other Raw Materials

By End-use:

  • Hospitals
  • Home Healthcare
  • Outpatient/Primary Care Facilities
  • Other End-uses

Unleash Potential: Craft Your Customized Report Now :
https://www.futuremarketinsights.com/customization-available/rep-gb-2227

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global GLP-1 Receptor Agonist Market is projected to surpass US$ 11.24 Billion by 2032, driven by the escalating diabetes crisis, as per FMI

GLP-1 Receptor Agonist Market
GLP-1 Receptor Agonist Market

Future Market Insights, a leading player in the pharmaceutical industry, anticipates substantial growth in the global GLP-1 receptor agonist market. According to recent industry reports, the market size is expected to reach an impressive US$ 4.0169 billion in 2022 and is projected to exhibit a robust Compound Annual Growth Rate (CAGR) of 10.84% through 2032. By the end of this period, the industry is forecasted to soar to an estimated US$ 11.24 billion.

This exponential growth is indicative of the increasing demand for GLP-1 receptor agonists, which play a crucial role in the treatment of various medical conditions, including diabetes. The rising prevalence of lifestyle-related diseases and the growing awareness of the effectiveness of GLP-1 receptor agonists contribute to this significant market expansion.

To Remain Ahead of Your Competitors, Request For A Sample! https://www.futuremarketinsights.com/reports/sample/rep-gb-12346

Future Market Insights is well-positioned to capitalize on this trend, having invested strategically in research and development to deliver innovative and high-quality GLP-1 receptor agonist solutions. Our commitment to advancing healthcare aligns seamlessly with the global health landscape, and we are dedicated to addressing the evolving needs of patients and healthcare providers.

Future Market Insights attributes its optimism for the future to a combination of innovative product development, strategic partnerships, and a commitment to addressing the evolving healthcare needs of a global population.

“We are thrilled to witness such remarkable growth projections in the global GLP-1 receptor agonist market. This underscores the importance of our ongoing efforts to innovate and deliver healthcare solutions that make a meaningful impact. Future Market Insights is committed to playing a pivotal role in advancing medical treatments and improving the quality of life for individuals worldwide.”

The company invites stakeholders, investors, and the media to stay tuned for further developments as Future Market Insights continues to drive progress and shape the future of healthcare.

Here are some key points about the GLP-1 Receptor Agonist Industry:

  • Market Growth: The GLP-1 receptor agonist market was experiencing robust growth due to the increasing prevalence of type 2 diabetes worldwide. Lifestyle changes, including poor diet and sedentary habits, have contributed to a rise in diabetes cases.
  • Competition: Several pharmaceutical companies were actively developing and marketing GLP-1 receptor agonists. Some of the notable brands in the market included Trulicity (dulaglutide), Victoza (liraglutide), Ozempic (semaglutide), and Bydureon (exenatide). These drugs were available in various formulations, including injectable pens and, in some cases, oral tablets.
  • Clinical Advancements: Pharmaceutical companies were continuously working on improving the efficacy and safety profiles of GLP-1 receptor agonists. There were ongoing clinical trials to explore new formulations, dosing regimens, and combination therapies to better manage diabetes and potentially address other metabolic disorders.
  • Market Expansion: While GLP-1 receptor agonists were primarily used for type 2 diabetes management, they were also being explored for other potential applications. Research was ongoing to investigate their role in weight management and cardiovascular disease prevention.
  • Cost and Accessibility: The cost of GLP-1 receptor agonists was a concern for some patients and healthcare systems. Access to these medications varied depending on geographical location and healthcare policies.

Reach Out To Our Analyst For Prompt Assistance With Your Questions! https://www.futuremarketinsights.com/ask-question/rep-gb-12346

Competition Analysis:

  • Eli Lilly and Company
  • Sanofi
  • Novo Nordisk A/S
  • AstraZeneca
  • Boehringer Ingelheim
  • Zealand Pharma A/S
  • Co., Ltd
  • GlaxoSmithKline plc.

Key Segmentation GLP-1 Receptor Agonist Industry:

Drug Class:

  • Exenatide
  • Liraglutide
  • Dulaglutide
  • Lixisenatide
  • Others

Route of Administration:

  • Parenteral
  • Oral

Distribution Channel:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Empower Your Business with Customization: Discover the Strategies in Our New Report! https://www.futuremarketinsights.com/customization-available/rep-gb-12346

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Mecoprop Market Set to Reach US$ 538.0 Million by 2033, FMI Forecasts

The global mecoprop market showcased a robust valuation of US$ 356.6 million in 2023, with projections indicating a steady expansion at a compound annual growth rate (CAGR) of 4.2% from 2023 to 2033. With this trajectory, the market is poised to reach a valuation of US$ 538.0 million by the conclusion of the forecast period. This anticipated growth underscores the increasing demand for mecoprop across various industries, driven by its effectiveness as a herbicide and its widespread application in agricultural and horticultural practices.

The global mecoprop market has experienced substantial growth in recent years, driven by the rising demand for herbicides that offer efficient weed control while minimizing environmental impact. Agricultural intensification, coupled with the need for higher crop yields to meet food demands, has propelled the use of mecoprop in crop protection practices. Additionally, the growing emphasis on sustainable farming practices has further augmented the adoption of mecoprop, given its favorable toxicological profile compared to other herbicides.

Get Your Sample Report – Drive Business Success! https://www.futuremarketinsights.com/reports/sample/rep-gb-10807

Key Market Drivers:

  1. Rising Agriculture Activities: The expanding agricultural sector, particularly in developing regions, has significantly contributed to the increased utilization of mecoprop. Farmers are increasingly relying on herbicides like mecoprop to enhance crop productivity by combating weed infestations effectively.
  2. Shift towards Integrated Weed Management (IWM): With growing concerns over herbicide resistance and environmental sustainability, there’s a notable shift towards integrated weed management strategies. Mecoprop, with its selective action and low persistence in the environment, aligns well with the principles of IWM, thus driving its demand.
  3. Urbanization and Landscaping Needs: The expanding urban landscape and heightened focus on aesthetics have led to greater demand for herbicides in landscaping and turf management. Mecoprop’s effectiveness in controlling broadleaf weeds in non-crop areas such as lawns, parks, and golf courses has fueled its adoption in the landscaping industry.

Mecoprop Market: Key Players

  • BASF SE
  • Corteva, Inc.
  • Syngenta
  • Monsanto Company
  • Bayer AG
  • FMC Corporation
  • Adama Agricultural Solutions Ltd.
  • Nufarm Ltd.
  • Conier Chem and Pharma Limited
  • Toronto Research Chemicals
  • DAYANG CHEM (HANGZHOU) CO., LTD.
  • Henan Allgreen Chemical Co., Ltd.
  • Angene Chemical Private Limited
  • Alfa Chemistry

Get in Touch with Our Sales Team to Secure Your Copy of the Report Now! https://www.futuremarketinsights.com/checkout/10807

Mecoprop Market: Segmentation

By Form:

  • Mecoprop
  • Mecoprop-P

By Application:

  • Herbicide
  • Pesticide
  • Others

By End-Use:

  • Agricultural
    • Pasture
    • Rangeland
    • Cropland
    • Others
  • Non-Agricultural
    • Residential Law
    • Recreational Turf
    • Sports Field
    • Sod Farm
    • Pavements
  • Others

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:       

Nandini Singh Sawlani  

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Opioid Use Disorder Treatment Market Targets US$ 8.4 Billion by 2033, Fueled by Buprenorphine’s 81.4% Growth

Opioid Use Disorder Treatment Market
Opioid Use Disorder Treatment Market

The global opioid use disorder treatment market sales is expected to be valued at an impressive US$ 3.07 billion in 2023 and increase at a compound annual growth rate (CAGR) of 10.5% to reach US$ 8.4 billion by 2033. Raising public awareness of the terrible effects of drug addiction and the importance of undergoing abuse treatment is the main objective of manufacturers and providers of drug abuse therapy, as well as drug store owners.

This increase their customer pool which directly aids in market expansion of Opioid use disorder treatment. Growing awareness through television advertisements, newspapers, information brochures, and other media are proving to be very effective in impeding the opioid abuse crisis to a certain extent.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16561

There are various organizations that are participating with other organizations that is leading to industry’s expansion. For example, in March 2016, GlaxoSmithKline collaborated with 2morrow Inc., developer of SmartQuit app to supply patches to smokers having the app plan. Similarly, In August 2013, the company agreed to distribute its Buprenorphine HCl and Naloxone HCl Dihydrate Sublingual Tablets (CIII), a generic version of Suboxon with Amneal Pharmaceuticals LLC , to the addiction treatment centers. This will benefit the market in the long-term.

On the other hand, addiction crisis over the past decade has driven the need to invest in integrated research and development activities which focus on addiction treatment and the recovery process. Even though the number of research activities pertaining to issues related to Opioid use disorder has increased at an impressive pace, stakeholders operating in the current treatment market landscape are progressively finding new methods to apply these findings into the real-world care delivery. This is expected to fuel market’s growth in the forthcoming period.

Some of the other factors propelling growth in this market include rising prevalence of diseases that cause chronic pain, such as cancer, lower back pain arthritis, fibromyalgia and postsurgical pain, interest toward extended-release formulations from the immediate release of opioids, and increasing focus on the abuse-deterrent formulation (ADF) by generic manufacturers.

In addition, in countries such as the United Kingdom, the National Health Service runs various public and privately funded programs for treatment of Opioid use disorder. Moreover, several companies adopt the strategies of merger and acquisition to bolster their market presence in new geographies or add new products and services or both to existing platforms, which helps the industry to grow. For example, in December 2015, Acadia Healthcare acquired Priory Group, a leading provider of behavioural care services in the United Kingdom. This acquisition was intended to expand Acadia Healthcare’s capacity and geographic presence in the United Kingdom which would help in growing overall market of Opioid use disorder treatment.

Elevate Strategy: Tap into Analyst Expertise Now:
https://www.futuremarketinsights.com/ask-question/rep-gb-16561

However, rising expenditure required for the diverse treatment processes is challenging market growth. Several market players make huge investments in manufacturing new and medically advanced treatment procedures to boost the recovery process, and in return, it increases treatment cost which then hamper the growth of industry.

Key Takeaways:

  • North America is expected to dominate the industry while reaching market share of around 48% by the end of the forecast period.
  • The market in East Asia is projected to reflect fastest CAGR of 8.8% during the projected timeline.
  • By drug class, Buprenorphine is projected to account for 81.4% market share by end of the forecast period.
  • Hospitals are expected to dominate the market by distribution channel, with a market share of 35% by 2033.

“Rising collaborations and mergers between companies, increasing research and development activities and adoption of technological advanced techniques for treating Opioid disorder will drive the industry’s growth,” comments an FMI analyst

Competitive Landscape

The Opioid use disorder treatment Market is competitive and consists of several major players. Major players are creating novel delivery systems for the treatment of opioid use disorder. This is expected to propel Opioid use disorder treatment market. The major players in the market are: Trevena, Opiate Pharmaceutical, Aphios, Kyowa kirin, Gamida-Cell, Novartis, Titan Pharmaceuticals, Inc., Hikma Pharmaceuticals, MediciNova, Alkermes, Inc., BioDelivery Sciences International, Inc.

Some recent developments in the market are:

  • In January 2022, Trevena, Inc. declared that China’s National Medical Products Administration (NMPA) has accepted the submission of a New Drug Application (NDA) for OLINVYK (oliceridine) injection, a novel IV analgesic that has been approved in the United States by the FDA for use in adults for managing acute pain severe enough to require an intravenous opioid analgesic.
  • In October 2021, Esteve Pharmaceuticals received authorisation from the United States Food and Drug Administration (FDA) for SEGLENTIS (celecoxib and tramadol hydrochloride) for the management of acute pain in adults that is extreme enough to require an opioid analgesic.
  • In January 2020, Titan Pharmaceuticals, Inc. made a revelation that they had entered into an agreement with AllianceRx Walgreens Prime for the expansion of accessibility of patients for Titan’s opioid use disorder implant branded as “Probuphine implant”.

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News. 

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Polyglycolic Acid Market Anticipates Impressive 10% CAGR by 2033

The global polyglycolic acid market is poised for remarkable growth, projected to achieve a compound annual growth rate (CAGR) of 10%, reaching a substantial market value of US$ 13 billion. This surge in demand for polyglycolic acid, a biodegradable polymer with versatile applications in industries ranging from medical to packaging, reflects its increasing adoption as a sustainable alternative to traditional materials. Factors such as growing environmental concerns, stringent regulations favoring eco-friendly products, and the burgeoning need for biodegradable materials drive the market’s expansion, positioning polyglycolic acid as a pivotal player in the global market landscape.

Polyglycolic Acid, a synthetic polymer of glycolic acid, boasts exceptional properties such as biodegradability, high tensile strength, and good mechanical properties. These attributes make it an ideal choice for applications in sectors like medical, packaging, shale gas extraction, and more. The market for PGA is witnessing steady growth, propelled by increasing environmental concerns and stringent regulations promoting the adoption of sustainable materials.

Transform Your Strategy: Request a Sample Report to Elevate Your Business! https://www.futuremarketinsights.com/reports/sample/rep-gb-11743

Key Growth Drivers:

  1. Medical Sector Advancements: PGA finds extensive utilization in the medical sector, particularly in absorbable sutures and tissue engineering, owing to its biocompatibility and predictable degradation profile.
  2. Rising Demand in Packaging: With the surge in demand for eco-friendly packaging solutions, PGA-based materials are gaining traction as a viable alternative to traditional plastics.
  3. Expanding Applications in Other Industries: PGA’s versatility extends to applications in agriculture, shale gas extraction, and construction, further augmenting its market growth.

Polyglycolic Acid Market: Top Key Players

  • Huizhou Foryou Medical Devices Co., Ltd. (China)
  • Kureha Corporation (Japan)
  • Corbion (Netherland)
  • Teleflex Incorporated (US)
  • BMG Incorporated (Japan)
  • Shenzhen Polymtek Biomaterial Co., (China)

Drive Your Business Growth Strategy: Purchase the Report for Key Insights! https://www.futuremarketinsights.com/checkout/11743

Polyglycolic Acid Market: Segmentation

The global market of Polyglycolic Acid can be segmented on the basis of type, form, end use industries, and manufacturing process:

On the basis of type

  • Racemic Polyglycolic Acid
  • Regular Polyglycolic Acid
  • Poly-DL-lactic acid

On the basis of form

  • Fibers
  • Films
  • Others (plate, rod and composites)

On the basis of end use industries

  • Medical
  • Oil & Gas
  • Packaging
  • Others (civil engineering, agriculture and filters)

On the basis of manufacturing process

  • Direct Polycondensatioal Reactions
  • Ring Opening Polymerization
  • Azeotropic Dehydrative Condensation

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:       

Nandini Singh Sawlani  

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Mucinoses Management Market Poised for Surge, Foreseeing 19.5% CAGR to Reach Nearly US$ 670 Million by 2033

Mucinoses Management Market
Mucinoses Management Market

From 2023 to 2033, the mucinoses management market trends is expected to develop at a compound annual growth rate (CAGR) of 19.5%, according on a recent report by Future Market Insights. By 2023, the market is projected to be worth US$112.81 million. Numerous factors, such as increased government funding for research and development and system changes that allow various health specialists to focus on providing enough volume while also ensuring medical providers do not stifle the quality of care, are expected to contribute to the growth of the mucinoses management market in the healthcare industry. The healthcare budget for the European Union in 2017 was US$ 1221 billion, or nearly 7.1% of GDP.

Enhanced occurrences of head and neck cancer will be a major driving factor for the North American severe oral mucositis industry to expand in the years ahead. The prominent competitors in the United States are focusing on fundraising to supplement studies and development for managing severe oral mucositis induced by radiation therapy and chemotherapy in cancer patients.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16543

As a result of this factor, North America is expected to see market growth. The growth of Asia Pacific can be attributed to government programs that assist orphan ailment patients. For example, the Indian government directed federal and state governments in July 2022 to ensure that healthcare programs evolved to treat patients suffering from orphan diseases.

Key Takeaways:

  • From 2018 to 2022, sales increased significantly, with an 18% CAGR.
  • In the United States, patients must pay an additional US$ 3,700 per loop for chemotherapeutic-induced oral mucositis.
  • In 2021, the severe oral mucositis market in the United States is expected to be worth US$ 79 million.
  • By 2033, the global mucinoses management market is expected to be worth US$ 669.95 million by 2033.
  • According to FMI, the European Mucinoses Management market will grow at a 17.1% value CAGR by 2033.

“The proactive approaches premised on ground-breaking initiatives to introduce innovative SMA medicines to resolve unmet medical requirements in rare disease therapeutics is expected to propel industry growth,” says an FMI analyst.

Key Players:

GSK plc, Almirall, S.A, Merck & Co., Inc, Bausch Health, Sandoz International GmbH, Pfizer Inc, AstraZeneca, Sanofi, Alencure Biotech, and Divine Laboratories are key players in the Mucinoses Management market. The following are some of the most recent developments by major manufacturers.

In July 2021, AstraZeneca paid US$ 13.3 billion for acquiring Alexion Pharmaceuticals, Inc. This acquisition strengthens the corporation’s rare disorder product portfolio and provides significant opportunities for expansion.

  • In June 2022, Pfizer acquired ReViral, a privately held clinical-stage biotech company. The acquisition will demonstrate the organization’s approach to progressing and innovating science through in-house competence as well as the partnership with renowned, revolutionary companies in order to deliver innovative significant developments to patient populations afflicted by serious contagious diseases such as mucinoses.

Key Segments:

By Drug Class:

  • Topical Corticosteroids
  • Corticosteroid Injections
  • Oral Antibiotics

By Route of Administration:

  • Oral
  • Intralesional
  • Topical

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Elevate Strategy: Tap into Analyst Expertise Now:
https://www.futuremarketinsights.com/ask-question/rep-gb-16543

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Gastro-retentive Drug Delivery Systems Market Targets US$ 24.8 Billion by 2033

Gastro-retentive Drug Delivery Systems Market
Gastro-retentive Drug Delivery Systems Market

According to a recently released Future Market Insights study, the gastro-retentive drug delivery systems market revenue is expected to generate sales of US$ 13.3 billion in 2022 and is predicted to increase at a CAGR of 10.1% from 2023-2033. The market is anticipated to reach US$ 24.8 billion by the end of 2033.

Large drug firms’ investments to enhance gastro-retentive drug-delivery systems, along with the reduction in required doses due to enhanced bioavailability and an increase in the requirements for medications, have helped accelerate the market growth. The well-established efficacy of gastro-retentive drug delivery systems in treating a variety of stomach disorders such as peptic ulcer and gastric ulcer, as well as a growth in the incidence of H. Pylori infection, which can cause gastritis and gastric cancer, impart a significant impact on the market.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16540

Gastro-retentive drug distribution technology has proven to be a useful way of regulating the administration of a wide range of medicinal substances while enhancing bioavailability. Advancements in controlled oral medication administration systems have been made in recent years because of technological advancements that overcome physical roadblocks such as unpredictable stomach emptying periods and short gastric residency times. By extending their dwell time in the upper GI tract, once-GRDDS can enhance oral bioavailability and therapeutic excellence.

Technological advancements for rate-controlled oral medication delivery systems are now overcoming physiological issues such as unexpected stomach emptying intervals and short gastric residency times. To address these issues, the gastro-retentive drug delivery system is designed for a longer stomach retention duration, which increases patient preference by extending the time available for medicine absorption.

North America is expected to account for significant revenue in the gastro-retentive drug delivery systems market, with a market projection of US$ 10 Billion. Regional expansion is expected to be facilitated by the introduction of improved gastro-retentive medication delivery technology and the implementation of novel treatment techniques in healthcare.

GRDDS are projected to be in high demand as the prevalence of gastrointestinal disorders grows in the United States and Canada, as they lengthen medication retention time in the stomach. Demand for these devices in the region is projected to be driven by the presence of a large patient pool. Rising research and development spending in emerging markets is expected to drive regional market expansion.

Competitive Analysis

Manufacturers will benefit from proprietary benefits such as industry research financing and product development agreements, which will help them contribute to the development of effective cancer diagnosis technologies. Obtaining patents and government clearances for new technology will also continue to be a key growth strategy. The key players in the market include Ranbaxy, F. Hoffmann La Roche, Pharmacia, GlaxoSmithKline, Lupin, Pfizer, Depomed, Galanix, Sun Pharma, and Alcon, Inc.

Few of the recent developments of key Gastro-retentive Drug Delivery Systems providers are as follows:

  • In 2020, Cadila Pharmaceuticals launched Esomeprazole tablets which will be used in treatment of hyperacidity and drug induced gastritis.
  • In 2020, Xiromed LLC launched 20mg Omperazole delayed release capsules. Omeprazole is cost effective generic product which can be used in treatment of gastroesophageal reflux disease and healing of erosive esophagitis.

Elevate Strategy: Tap into Analyst Expertise Now:
https://www.futuremarketinsights.com/ask-question/rep-gb-16540

More Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the Gastro-retentive Drug Delivery Systems Market, presenting historical market data (2018-2022) and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights by Type (High-Density System, Expandable Drug Delivery System, Bioadhesive Drug Delivery System, Floating Drug Delivery System, Others), by Dosage Form (Tablets, Liquid, Microspheres, Capsule, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), across five regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).

Market Segments Covered in Gastro-retentive Drug Delivery Systems  Industry Analysis

By Type:

  • High Density System
  • Expandable Drug Delivery System
  • Bioadhesive Drug Delivery System
  • Floating Drug Delivery System
  • Others

By Dosage Form:

  • Tablets
  • Liquid
  • Microspheres
  • Capsule
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Unleash Potential: Craft Your Customized Report Now:
https://www.futuremarketinsights.com/customization-available/rep-gb-16540

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Personalized Medicine Market Envisions US$ 690.9 Billion Potential by 2033

Personalized Medicine Market
Personalized Medicine Market

The recently published analytical report on the personalised medicine market trends by Future Market Insights projects that global sales of this market will reach US$ 326.7 billion by 2022. With a compound annual growth rate of 7.8% from 2023 to 2033, the country’s market is predicted to reach US$ 690.9 billion by 2033. With a compound annual growth rate (CAGR) of more than 6.5% from 2023 to 2033, personalised nutrition and wellness is anticipated to generate the most revenue.

In recent years, a significant focus is on how to employ advanced analytics, customized drugs, patient data, and other tools to better identify and treat illnesses. People are becoming more aware of the benefits of personalized treatment, and more genetic databases are being developed. These factors have been driving the global market for personalized medicine.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1511

More patients using personalized medication might help neurology, lung medicine, antiviral medicine, and psychiatry. This would broaden the global market for personalized treatment. The global personalized medicine market is also faltering as a result of increased research and development costs and poor side effects.

Over the forecast period, the personalized medicine market is expected to grow as more people develop chronic illnesses such as diabetes and cancer, more people receive combination pharmacological therapy, the global population ages, and more clinical studies for personalized medicine are conducted in neurology departments.

However, the exorbitant cost of customized drugs is stifling business growth. Due to the favorable government reimbursement criteria and low medical defect and side effect concerns, the market is expected to grow.

The growing number of cancer types and the low cost of personalized medicine therapy in cancer medications are expected to boost the global personalized medicine market. Cancer killed more than 9 million people in 2018, according to the World Health Organization. It kills almost one out of every six people worldwide.

North America was the prominent market for personalized medicines. The development of next-generation sequencing technologies and the implementation of health information technology systems are assisting in the expansion of the personalized medicine industry in North America. These technologies make it simple to get customized pharmaco-genomic information in a timely and convenient manner.

Elevate Strategy: Tap into Analyst Expertise Now:
https://www.futuremarketinsights.com/ask-question/rep-gb-1511

Competitive Analysis:

The precision medicine industry is moderately competitive, with several large corporations as well as a slew of smaller businesses vying for clients’ attention. Because of technological advancements and product improvements, the introduction of new technologies at low cost is assisting mid-size to small businesses in expanding their market presence. Among the firms with a strong presence in the sector are Medtronic PLC, Pfizer Inc., Novartis AG, Qiagen, and Teva Pharmaceuticals.

Recent developments by leading providers are as follows:

  • In February 2021, Illumina, Inc. entered into a study agreement with the Belgian Society of Medical Oncology to investigate Comprehensive Genomic Profiling in advanced metastatic cancer patients.
  • In January 2019, Metagenics, Inc. announced that it has introduced a clinical research laboratory and patient clinic named Personalized Lifestyle Medicine Center in Washington.

Key Players:

  • GE Healthcare
  • Illumina, Inc.
  • ASURAGEN, INC.
  • Abbott
  • Dako A/S
  • Exact Sciences Corporation
  • Cepheid, Inc.
  • Decode Genetics, Inc.
  • QIAGEN
  • Exagen Inc.
  • Precision Biologics
  • Celera Diagnostics LLC
  • Biogen

More Insights Available:

Future Market Insights, in its new offering, presents an unbiased analysis of the Personalized Medicine Market, presenting historical market data (2018-2022) and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights by Type (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, Personalized Nutrition & Wellness) across five regions (North America, Latin America, Europe, APAC and Middle East & Africa).

Unleash Potential: Craft Your Customized Report Now:
https://www.futuremarketinsights.com/customization-available/rep-gb-1511

Market Segments Covered:

By Type:

  • Personalized Medicine Diagnostics
    • Genetic Testing
    • DTC Diagnostics
    • Esoteric Lab Services
    • Esoteric Lab Tests
  • Personalized Medicine Therapeutics
    • Pharmaceutical
    • Genomic Medicine
    • Medical Devices
  • Personalized Medical Care
    • Telemedicine
    • Health Information Technology
  • Personalized Nutrition & Wellness
    • Retail Nutrition
    • Complementary & Alternative Medicine

By Region:

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Hyperpigmentation Treatment Market Aims for 8.6% Value CAGR by 2033

Hyperpigmentation Treatment Market
Hyperpigmentation Treatment Market

The hyperpigmentation treatments market share is expected to develop at a compound annual growth rate (CAGR) of 8.6% from 2023 to 2033, with a projected value of US$ 4.78 billion. A tiny drop in melanin production leads to skin darkening. Hyperpigmentation disorders can be treated with chemical peels, cosmeceuticals, and laser treatment. The prevalence of melasma is rising, and a comprehensive understanding of treatment options for hyperpigmentation is also having an impact on the worldwide hyperpigmentation industry.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16510

The popularity of the Hyperpigmentation Treatment Market is increasing due to a steady stream of new product releases and asset utilization by significant prominent stakeholders in research and development. Furthermore, rising demand for outpatient and microsurgical processes is anticipated to lead to lucrative opportunities in the Hyperpigmentation Treatment Market in the coming years. Furthermore, the global economy for hyperpigmentation Disorders Treatment may suffer as a result of insufficient favorable reimbursement and high demand for cosmetic procedures.

Dermabrasion practices, such as enhanced us and of lasers in the diagnosis of pigmentation disorders and rising cosmetics spending globally, are expected to drive market growth. Researchers have been investigating how nanotechnology can improve active substance delivery and ingestion to the skin, in addition to the efficacy of specific therapeutic drugs. Because of its ability to improve the properties of skincare products in general, nanotechnology has emerged as a feasible addition to beauty products.

Key Takeaways:

  • Hyperpigmentation Treatment market is predicted to exceed an impressive valuation of US$ 4.78 billion in 2023.
  • Sales increased significantly from 2018 to 2022, with a CAGR of 7.1%.
  • In 2021, Asia Pacific will account for approximately 36% of the global hyperpigmentation disorder services market.
  • The crystal microdermabrasion device segment in the United States is projected to expand at a CAGR of 9% during the forecast period.
  • The global Hyperpigmentation Treatment market is anticipated to be worth US$ 11.84 billion by 2033.

“Offering laser therapy and phototherapy to help the industry grow over the next few years. Moreover, automakers that treat hyperpigmentation illnesses have lucrative deals as a result of technological advances in cosmeceuticals and a boost in the use of pharmaceuticals in skincare.” says FMI’s analyst.

Key Market Players

Key players in the Hyperpigmentation Treatment market are Episciences, Vivier Pharma, La Roche-Posay, Pierre Fabre Dermo Cosmetique, Bayer, Alvogen, Allergen, Obagi Medical Products, SkinCeuticals International, and L’Oréal Paris.

  • In September 2022, L’Oréal acquired Skinbetter Science, a practitioner U.S.-based skincare brand backed by cutting-edge dermatological science that combines internally developed efficacious additives with glamorous sensorial textures.
  • Obagi Medical Products introduced the Obagi Nu-Derm® Systems in October 2022, which help to convert skin by addressing hyperpigmentation and improving visible signs of aging.

Key Segments Profiled in the Hyperpigmentation Treatment Market Industry Survey

By Type:

  • Pharmacological Therapy
  • Laser Treatment
  • Chemical Peels and Bleach
  • Microdermabrasion
  • Skin Grafting or Plastic Surgery

By Application:

  • Skin Clinics
  • Drug and Cosmetic Stores
  • Hypermarkets and Supermarkets

Elevate Strategy: Tap into Analyst Expertise Now:
https://www.futuremarketinsights.com/ask-question/rep-gb-16510

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Hypoventilation Management Market Sets Sights on US$ 11.9 Billion by 2033

With a projected growth rate of 5.3% over the course of the forecast period, the worldwide hyperventilation management market trends is likely to surpass an outstanding valuation of US$ 7.1 billion in 2023 and reach US$ 11.9 billion by 2033. Obesity may result from youth’s increased access to and popularity of high-calorie foods. This in turn leads to a host of illnesses, including sleep difficulties. The market expansion of hypoventilation diagnostic equipment is primarily being driven by this important aspect. Early diagnosis of the issue can be facilitated by the use of sleep diagnostic tools. Thus, this is thought to be one of the main causes of the rise in the use of hypoventilation diagnostic tools.

Hypoventilation disorder diagnostic devices such as Positive Airway Pressure (PAP) devices have witnessed significant development in terms of design, efficacy, and safety has helped to boost the adoption of products and patient outcomes. Moreover, small PAP devices for individual use at home and the availability of cheaper brands are anticipated to fuel the growth of the hypoventilation devices market over the forecast period.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16517

Key players in the market are involved in improving the overall hypoventilation treatment paradigm by introducing medical devices, web-based applications, and other efforts to reduce the global burden of hypoventilation disease which is estimated to drive the market growth during the forecast period. For instance, in May 2019, Spire Health, a healthcare company launched a study to develop new digital biomarkers that can predict exacerbations and potential hospitalizations in patients with severe Chronic Obstructive Pulmonary Disease which is a type of hypoventilation disease.

Factors such as awareness initiatives by organizations, the growing prevalence of Chronic obstructive pulmonary disease, and product launches are propelling hypoventilation treatment market growth. For instance, in May 2019, Boehringer Ingelheim and Optimum Patient Care declared the creation of a new patient registry, APEX COPD, to better understand various types of hypoventilation disorders and how they can be typically treated in primary care offices. Such initiatives by market players are projected to boost market growth over the forecast period. Moreover, a pipeline for hypoventilation diseases and mainly COPD has several potential medications, which are anticipated to drive hypoventilation treatment market growth during the forecast period.

Key Takeaways:

  • North America is expected to dominate the industry while reaching a market share of around 41% by end of the forecast period.
  • The market in South Asia is projected to reflect a CAGR of 5.5% during the projected timeline.
  • By disease type, chronic obstructive pulmonary disease is anticipated to account for maximum market share of 55% during the forecast period.
  • Hospitals are projected to account for 71% market share by end-user, by end of 2033.

“Adoption of positive airway pressure devices and other product launches will bolster hypoventilation treatment market in the forecast period”- comments an FMI Analyst

Competitive Landscape:

The global Hypoventilation management market is highly competitive a due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are: Accord Healthcare Limited, Avet Pharmaceuticals Inc, Nostrum Laboratories Inc, Lannett Co Inc, Strides Pharma Science Limited, X Gen Pharmaceuticals Inc, ResMed, Koninklijke Philips NV, Hikma Pharmaceuticals, Lincare Holdings

 Some recent developments in this industry are:

  • In June 2022, Verona Pharma, a pharmaceutical company announced the completion of the patient enrolment, with more than 800 subjects involved for its randomized ENHANCE-1 trial. The study will evaluate ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease, a type of hypoventilation disorder. It is a critical step for the phase III ENHANCE trial with top-line data expected by the end of the year 2022 and further data from ENHANCE-2 in the third quarter of 2022.
  • In November 2021, AstraZeneca announced that it had sold rights to sell Tudorza, also known as Eklira abroad, and Duaklir to the Switzerland-based pharmaceutical company Covis Pharma Group for US$ 270 Mn. These products are indicated for the treatment of various types of hypoventilation disorders
  • In May 2022, Alembic Pharmaceuticals Ltd, a pharmaceutical company, received final approval from the U.S. health regulator for its generic version of Arformoterol Tartrate inhalation solution indicated for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. The approval by the U.S. Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for strength of 15 mcg (base)/2 mL unit-dose vial.

More Valuable Insights Available

Future Market Insights offers an unbiased analysis of the global hypoventilation management market, providing historical data for 2018-2022 and forecast statistics from 2023-2033.

To understand opportunities in the Hypoventilation management market, the market is segmented on the basis of disease type (Chronic obstructive pulmonary disease, Obesity hypoventilation syndrome, Central alveolar hypoventilation, Neuromuscular disorders) by treatment (Oxygen therapy, Non-invasive mechanical ventilation, Drug therapy) by end-users (Hospitals, Specialty clinics, Home care) by region (North America, Latin America, Europe, South-Asia, East-Asia, Oceania, Middle East, and Africa)

Unleash Potential: Craft Your Customized Report Now:
https://www.futuremarketinsights.com/customization-available/rep-gb-12415

Key Segments:

By Disease Type:

  • Chronic Obstructive Pulmonary Disease
  • Obesity Hypoventilation Syndrome (OHS)
  • Central Alveolar Hypoventilation
  • Neuromuscular Disorders

By Treatment Type:

  • Oxygen Therapy
  • Non-Invasive Mechanical Ventilation
  • Drug Therapy

By End User:

  • Hospitals
  • Specialty clinics
  • Home care

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube